Navigation Links
Overcoming Challenges in Amblyopia Detection using Visual Evoked Potential (VEP)
Date:7/30/2012

PINE BROOK, N.J., July 30, 2012 /PRNewswire/ -- Vision Problems in infants and pre-verbal children are a challenge for ophthalmologists and optometrists to diagnose and manage. Many vision tests look at just the structure of the eye or require a verbal response which many children are either unable or unwilling to give. Dr. Sean Donahue and colleagues at Vanderbilt Eye Institute in Nashville, TN recently presented a poster, Visually Evoked Potential Detection of Amblyopia in the Clinic, at the annual American Association for Pediatric Ophthalmology and Strabismus (AAPOS) meeting. Their research helps provide a solution to eye care specialists for their pediatric patients.

Office-based visual evoked potential (VEP) technology from Diopsys, Inc. allows eye care professionals to objectively measure the function of the entire visual pathway without the patient having to say a word. VEPs are electrical signals ("brain waves") that are measured at the visual cortex. VEPs occur when a patient observes a visual stimulus, such as a flash of light or a pattern on a monitor. VEP results are a representation of the functional integrity of the visual system including the retina, optic nerve, optic radiations, and visual cortex.

Dr. Donahue used this technology to develop a user and patient friendly test to aide in the diagnosis and management of amblyopia in children. He describes amblyopia as "poor vision in an eye that otherwise appears normal and occurs when the brain does not recognize the sight from that eye. Eventually, the brain stops using the weaker eye, causing poor vision or even permanent visual impairment."

By testing both normal children and children with amblyopia with the Diopsys® NOVA-TR system, researchers found that a simple 5-minute VEP protocol correctly identified children with amblyopia more than 80% of the time. "This is important since fixation preference testing can be unreliable in detecting amblyopia in preverbal children," said Dr. Donahue. Additionally, the researchers found that this testing method correctly identified normal patients nearly 94% of the time, and could also help classify patients with amblyopia as "mild" or "moderate to severe."  This study was so successful the poster went on to win "Best in Show" at the meeting.

The Diopsys® NOVA-TR VEP Vision Testing System is easy to use, non-invasive, and testing times are flexible and depend upon the customized settings designated by the clinician. Automation of the test protocol used for the study, the Diopsys® NOVA-PED, is currently under development and is projected to be available later this year.

Diopsys, Inc. (www.diopsys.com) is a medical instrumentation company dedicated to delivering high-quality, cost-effective preventative health care solutions. The company specializes in the development and marketing of patient-friendly, non-invasive vision testing equipment utilizing Visual Evoked Potential (VEP) technology.


'/>"/>
SOURCE Diopsys, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The Biomedical Device Industry in America: Challenges at Home and Abroad
2. Pharma Execs Continue Looking For Growth Opportunities In Spite Of Increasing Regulatory Challenges: KPMG Survey
3. International Drug & Explosives Detection Company Identa Corp to Dispatch First Order to Drug Store Chain
4. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
5. Trovagene to Study Trans-Renal KRAS Mutation Detection in Pancreatic Cancer
6. Breast Cancer Detection and Treatment Recovers Slowly from Big Losses During Recession
7. ChemDAQ Releases First Sensor For Detection Of Peracetic Acid In Air
8. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
9. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
10. Largest Public Hospital in Sydney Delivers First Treatment in Australia Using Advanced TrueBeam Radiotherapy and Radiosurgery Device
11. Partnership Aims to Prevent Students from Misusing Prescription Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... -- New research provides evidence that an old drug may provide ... released today that will be presented at the American ... Boston , April 22 to 28, 2017. ... the oral drug levodopa has long been considered the gold ... disease progresses, the effects of the medication can partially wear ...
(Date:4/19/2017)... April 19, 2017  SARES•REGIS Group leased the ... developing at Conejo Spectrum Business Park in ... Atara Biotherapeutics, Inc. , a biopharmaceutical company developing ... diseases that have been underserved by scientific innovation, ... for cancer, autoimmune and infectious disease. ...
(Date:4/18/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical ... Gynecology markets with innovative and proprietary products, will release ... 2017 after the market close on Tuesday, May 2, ... conference call and webcast to discuss its financial results ... 4:30 p.m. Eastern Time (3:30 p.m. Central Time). ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... ... Saad B. Chaudhary, MD is committed to providing the highest quality of spine care to ... preventative care with all my patients to alleviate possible future issues. I am pleased to ... my office and my trained staff will assist you in any way possible.” , Dr. ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol ... is introducing Flexadin UCII, part of the EQUISTRO line, at this week’s Rolex ... in horses at the immunologic level. , The scientifically-developed Flexadin UCII supports the ...
(Date:4/24/2017)... ... ... Michael Vick announced his retirement earlier this year from the NFL after thirteen ... in the 2001 NFL Draft, to the Atlanta Falcons, made four Pro Bowl appearances ... yards by a quarterback (6,109) and the most rushing yards by a quarterback in ...
(Date:4/24/2017)... ... April 24, 2017 , ... NEPC Director Kevin Welner has ... Research Award. The award honors scholars exemplary in their capacity to communicate important ... has demonstrated the capacity to deepen the public’s understanding and appreciation of the ...
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... Sean Fay ... Oxiclean, Space Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which sold ... any other marketer in the last 25 years. , Now, due to changes in ...
Breaking Medicine News(10 mins):